# ALPHAMAB ONCOLOGY

### 康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)
(Stock Code 股份代號: 9966)

Dear registered shareholder(s),

7 February 2024

#### **Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Alphamab Oncology (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at <a href="https://www.alphamabonc.com">www.alphamabonc.com</a> and the HKEXnews website at <a href="https://www.hkexnews.hk">www.hkexnews.hk</a> in place of printed copies.

Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form on the reverse side (the "**Reply Form**"). Alternatively, you may sign and return the Reply Form to the Company's Hong Kong share registrar (the "**Share Registrar**"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete and return the Reply Form to the Share Registrar or send an email to <a href="mailto:alphamab-b.ecom@computershare.com.hk">alphamab-b.ecom@computershare.com.hk</a> specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please send an email to the Share Registrar at alphamab-b.ecom@computershare.com.hk,

Yours faithfully,
By order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Note: Actionable Corporate Communications are any corporate communications that seek instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

各位登記股東:

## 以電子方式發布公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發布公司通訊規定下香港聯合交易所有限公司證券上市規則 (「上市規則」)第 2.07 條, **康寧傑瑞生物製藥**(「公司」)謹此通知 閣下,公司已採用以電子方式發布公司通訊(「公司通訊」)之安排,該公司通訊是指公司發布或將要發布的任何文件,包括但不限於(a)董事報告、年度帳目以及審計報告副本以及(如適用)財務摘要報告; (b)中期報告及其中期報告摘要(如適用); (c)會議通知; (d)上市文件; (e)通函;和 (f)委任表格。

請注意,所有未來公司通訊的英文版和中文版將在公司網站 www.alphamabonc.com 和披露易網站 www.hkexnews.hk 上提供,以代替印刷本。

徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(開註)</sup>,公司建議 閣下透過掃描本函背頁之回條(「**回條**」)上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。 或者, 閣下也可以簽署回條並交回公司的香港股份過戶登記處(「**股份過戶處**」)香港中央證券登記有限公司,地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果公司沒有收到 閣下的有效電子郵件地址,直至股份過戶處收到 閣下有效的電子郵件地址前,本公司未來將以印刷本形式發送可供採取行動的公司通訊 (Mic)。

若 閣下希望收取公司通訊之印刷版,請填妥回條並交回股份過戶處,或發送電子郵件至 <u>alphamab-b.ecom@computershare.com.hk</u>,並 註明 閣下的姓名、地址以及收取公司通訊印刷版的要求。 請注意,收取未來公司通訊印刷版之指示由收悉 閣下指示當日起計一 年內有效,此後將過期。

如 閣下對本函件有任何疑問,請發送電子郵件至 alphamab-b.ecom@computershare.com.hk 與股份過戶處聯絡。

承董事會命 康寧傑瑞生物製藥 董事長兼執行董事 徐霆博士 謹啟

REPI	IV	FO	DM	回條
KPPI	1 / Y	T.	IK VI	101111

To: Computershare Hong Kong Investor Services Limited (The "Share Registrar")

17M Floor, Hopewell Centre

183 Queen's Road East, Wan Chai, Hong Kong

致: 香港中央證券登記有限公司

(「股份過戶處」) 香港灣仔皇后大道東 183 號

合和中心 17M 樓

(Please **choose ONLY ONE** of the options below) (請從以下選項中**只選擇其中一項**)

Personalized QR Code 專屬二維碼

Option 1: Provide email address for receipt of future Actionable Corporate

 $\textbf{Communications}^{(\textit{Note 3})} \ \textbf{of the Company via electronic dissemination by scanning}$ 

personalized QR code

選項1:

掃描 專屬二維碼提供電子郵件地址,以接收公司通過電子方式

發佈的可供採取行動的未來公司通訊<sup>(附註 3)</sup>

Returning this Reply Form is **NOT required** if Option 1 is chosen.

如選擇了選項1,無須交回本回條。

Option 2:   I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications (Note 3) of the following listed company (the "Company") via electronic dissemination   選項 2:   本人/吾等現以書面提供本人/吾等的電子郵件地址・以確保收到以下上市公司(「公司」)通過電子方式發佈的可供採取行動的未來公司通訊 (問註3)						
Name of Securities holder(s) 證券持有人姓名:	Name of the listed company 上市公司名稱: ALPHAMAB ONCOLOGY					
Email address 電郵地址: (Notes 3 / 附註 3)						

Option 3:							
receive future Corporate Communications* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Notes 5)							

Signature(s):	(Notes 1)
<b>ダ々</b> . (附計1)	

Contact number: 聯絡電話號碼:

Date:

日期:

- Notes 附註:

  1. Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.

  请清楚填妥 閣下之所有資料。如圖聯名股東,則本回條須由所有聯名股東聯合簽書,方為有效。

  2. Any Reply Form with no signature or otherwise incorrectly completed will be void.

  任何问题格若未有養養政在其他方面傳寫不证確,如本回條須由所有聯名股東聯合簽書,方為有效。

  3. If the Company does not receive a functional email address in your reply, you will be unable to receive notifications regarding the publication of Corporate Communications\*. Actionable Corporate Communications are any corporate communications that seek instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.

  如公司沒有收到 閣下的有效養子都中地, 閣下將未決則有關發格公司通訊》の資保報行動的公司通訊を任何涉及要求發行人的證券持有人指示其擬如何行使其有關證券持有人的權利的公司通訊。

  4. 拼 you provide more than one email address by QR code, email, reply form and/or other means, only the latest one email address provided will be registered.

  如 閣下獲過二維務、覆部、回條及項其他方式提供多於一個的電子郵件地址,只有 閣下最後提供的電子郵件地間會看到來如試會被用於登記。
- 如 周下地地上標等。電影 | 四級以供集地方和磁铁多水 | 回回電子野井地址、大海 | 画 微硬性状的電子野井地址が胃酸的水量能。

  5. If you mark "\" in the box in Option 3, no email address will be received.
  如 周下在護頂 3 方格内動上「√」 號・將不會有電子郵件地址被登記・只有公司通訊\*約日刷版會被收取。

  6. For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.
  高兔存裝・在本回線上的任何競外指示・公司將不予處理。

- specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to the annual report, interim report, notice of meeting, circular and proxy form. 除非另有註明·公司通訊乃指公司已發出或將予發出以供其任何證券的持有人參照或採取行動的任何文件·其中包括但不限於年報、中期報告、會議通告、通函及代表委任表格。

## PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- || 「中下sonal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").
  本登明中所指的「個人資料・與着港法例第 486 章 (個人資料(私膳)條例)」(「私膳等(條例)」)中「個人資料」的遊義相同。

  Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or requests as stated in this Reply Form.

  | 関下放本回條所提供的個人資料解用於包括但不限於分類器公司以電子方式發布公司通訊及就 関下持有的公司證券有關的其他事宜上與 閣下聯絡。間下是自願向本公司提供個人資料。若 閣下未能提供足夠資料。

  本公司可能無法經單間下在本回降上戶時途的指示及政委要。

  Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes,

  公司可就任何所說明的用途或在法例规定的情况下。將 閣下的個人資料授業或轉移給公司的附屬公司、股份過戶應、及/或其他公司或團體。並將在適業期間保留該等個人資料作核費及紀錄用途。

  You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer of computering the provision of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at PrivacyOfficer of computerior decomputers are constituted.
- (iii)
- tivacyOfficer@computershare.com.hk. 下与權權權。在被權務例,的條文查閱及或修改。關下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式郵寄至般份過戶處(地址為香港灣仔皇后大道東 183 號合和中心 17M 樓)向香港隱私主提出,或發送電郵至 <u>PrivacyOfficer@computershare.com.hk</u>。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited 香港中央證券登記有限公司 Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時・請將郵寄標籤剪貼於信封上 如在本港投寄・ 閣下無需支付郵費或貼上郵票。